振德医疗(603301) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,300,476,798.62, representing a year-on-year increase of 2.82%[5] - Net profit attributable to shareholders was CNY 146,461,478.20, reflecting a significant increase of 30.92% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 140,905,813.96, up by 40.80% year-on-year[5] - Basic earnings per share were CNY 0.55, an increase of 10.00% year-on-year, while diluted earnings per share also rose by 12.24% to CNY 0.55[5] - Total operating revenue for Q1 2023 was ¥1,300,476,798.62, an increase of 2.1% compared to ¥1,264,804,817.53 in Q1 2022[18] - Net profit for Q1 2023 reached ¥147,985,140.95, a 26.4% increase from ¥117,009,646.57 in Q1 2022[20] - Earnings per share for Q1 2023 were ¥0.55, compared to ¥0.50 in Q1 2022, indicating a growth of 10%[20] - The company reported a total comprehensive income of ¥169,129,872.78 for Q1 2023, compared to ¥117,009,646.57 in Q1 2022, indicating a significant increase[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -205,371,184.05, a decrease of 273.44% compared to the previous year[5] - In Q1 2023, the company's cash inflow from operating activities was CNY 1,397,604,503.80, a decrease of 3.93% compared to CNY 1,454,945,120.54 in Q1 2022[22] - The net cash flow from operating activities was negative at CNY -205,371,184.05, contrasting with a positive CNY 118,412,693.12 in the same period last year[22] - Total cash outflow from operating activities increased to CNY 1,602,975,687.85, up from CNY 1,336,532,427.42 in Q1 2022, marking a rise of 19.9%[22] - The company reported a net cash flow from investing activities of CNY -387,477,924.05, worsening from CNY -232,350,285.63 in Q1 2022[23] - Cash inflow from financing activities was CNY 534,900,000.00, an increase of 37.5% compared to CNY 389,000,000.00 in Q1 2022[23] - The net cash flow from financing activities improved to CNY 474,244,778.31, compared to CNY 131,754,828.90 in the previous year[23] - The ending balance of cash and cash equivalents was CNY 1,933,679,374.82, up from CNY 1,331,217,048.92 in Q1 2022[23] - The company experienced a negative impact of CNY -8,335,479.50 from foreign exchange fluctuations on cash and cash equivalents[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,119,014,236.49, up 2.81% from the end of the previous year[6] - The total liabilities as of Q1 2023 were ¥2,187,697,538.68, slightly up from ¥2,139,939,039.32 in Q1 2022[16] - The total current liabilities increased to RMB 1,292,000,000.00 from RMB 1,200,000,000.00, reflecting a rise of approximately 7.7%[15] - The company's cash and cash equivalents decreased to RMB 1,948,595,711.94 from RMB 2,075,107,919.75, representing a decline of about 6.1%[14] - The company's inventory remained stable at RMB 931,538,922.77, slightly up from RMB 929,587,857.11, indicating a marginal increase[15] - The company's goodwill increased to RMB 577,208,353.10 from RMB 474,485,730.66, showing an increase of about 21.7%[15] - The total equity attributable to shareholders increased to ¥5,716,303,658.29 in Q1 2023, compared to ¥5,541,678,060.39 in Q1 2022, reflecting a growth of 3.2%[16] Business Operations - The company reported a decrease of 22.72% in the main business income from isolation protective products, while excluding this, the main business income increased by 21.54%[8] - Research and development expenses increased to ¥42,093,960.50 in Q1 2023, up from ¥32,913,801.70 in Q1 2022, marking a rise of 27.7%[18] - The company completed the acquisition of 100% equity in Jiangsu Yinbeisi Technology Development Co., Ltd. for RMB 24,330,000, focusing on pre-filled catheter flushing products[13] - The company’s subsidiary, Rocialle Healthcare, acquired 100% of Dene Healthcare Limited for GBP 1,737.16 million, with the transaction completed in January 2023[13] - The company established FULLCARE (KENYA) MEDICAL SEZ LIMITED with a registered capital of 120,000 million Kenyan Shillings, focusing on wound care and surgical infection control products[12] - The company's trading financial assets increased to RMB 255,757,608.95, up from RMB 99,667,468.12, marking a significant increase of approximately 156.5%[14] - The total cash outflow for investing activities was CNY 387,640,364.33, significantly higher than CNY 239,982,604.95 in Q1 2022[23]